The targeted drugs developed for lung adenocarcinoma such as EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor, are largely ineffective against SqCLC [7]. This evidence concerns the gene EGFR and lung adenocarcinoma.